Cargando…

THU097 Primary Overproduction Of TSH Presenting As Intermittent Atrial Fibrillation Responding To Methimazole

Disclosure: T.D. Maher: None. Background: Intermittent Atrial Fibrillation (IAF) is commonly associated with Hyperthyroidism. TRH from the hypothalamus stimulates TSH production in the pituitary; a negative feedback loop of thyroxine to the hypothalamus is the primary regulator of TSH production. Th...

Descripción completa

Detalles Bibliográficos
Autor principal: Maher, Thomas D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553885/
http://dx.doi.org/10.1210/jendso/bvad114.1177
_version_ 1785116280285560832
author Maher, Thomas D
author_facet Maher, Thomas D
author_sort Maher, Thomas D
collection PubMed
description Disclosure: T.D. Maher: None. Background: Intermittent Atrial Fibrillation (IAF) is commonly associated with Hyperthyroidism. TRH from the hypothalamus stimulates TSH production in the pituitary; a negative feedback loop of thyroxine to the hypothalamus is the primary regulator of TSH production. The Pituitary is adjacent to the sphenoid sinus; nasal and sinus inflammation and other factors may affect TSH production. With currently available thyroid tests it is a clinical challenge to be certain the thyroid is not contributing to IAF. Clinical Case: A 72-year-old male presented at age 57 (2007) with new onset IAF. The patient had Allergic Rhinitis since age 20. For IAF he was treated with Metoprolol, Flecanide and Dofenilide but IAF continued. On 3/2/11, TSH was 5.12 ((0.270-4.2 uU/Ml). At age 64 (2014), Catheter Ablation was performed. Before the Ablation, 08/16/2013, the FT4 was 1.2 (0.90-1.70) ng/ml and TSH 3.99 (0.270-4.200) uU/ml. Two years post Ablation, on 1/19/2016, TFTs were: FT4 1.10 (0.90-1.70) ng/ml; TSH 5.42 (0.270-4.200) uU/ml and repeat TFTs on 3/15/16 were: FT4 1.24 (0.90-1.70) ng/dl; TSH 4.10 (0.270-4.2 uU/dl. The diagnosis of Borderline Hypothyroid was entertained. He was trialed on Thyroxine 25 mcg daily with gradual increase to 75 mcg. The patient complained of being light headed, weak and having diffculty concentrating and the TSH was still elevated. Thyroxine was discontinued. In 2017, IAF returned. In October 2019 the thyroid was 35-40 Gm., firm, and with small nodules on palpation and ultrasound. The TFTs on 10/01/2019 were: FT4 0.81 (0.75-1.54) ng/ml and TSH 5.15 (0.3-4.2) uIU/ml. To test whether overproduction of TSH was causing excess Thyroxine release and IAF, low dose Methimazole was started at 5 mg, four days a week. There have been no episodes of AF for the past three years while on Methimazole. TFTs on 10/19/2022 were: FT4 0.94 (0.75-1.54) ng/ml and TSH 7.11 (0.099-4.2) uiU/m). Conclusion: In the clinical setting of IAF, elevated TSH and normal FT4, overproduction of TSH by extrinsic stimuli should be considered. Thyroid partial blockade with Methimazole is safe, economical, and reversible and may give valuable information about whether the thyroid is causing episodic Atrial Fibrillation. Presentation: Thursday, June 15, 2023
format Online
Article
Text
id pubmed-10553885
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105538852023-10-06 THU097 Primary Overproduction Of TSH Presenting As Intermittent Atrial Fibrillation Responding To Methimazole Maher, Thomas D J Endocr Soc Neuroendocrinology & Pituitary Disclosure: T.D. Maher: None. Background: Intermittent Atrial Fibrillation (IAF) is commonly associated with Hyperthyroidism. TRH from the hypothalamus stimulates TSH production in the pituitary; a negative feedback loop of thyroxine to the hypothalamus is the primary regulator of TSH production. The Pituitary is adjacent to the sphenoid sinus; nasal and sinus inflammation and other factors may affect TSH production. With currently available thyroid tests it is a clinical challenge to be certain the thyroid is not contributing to IAF. Clinical Case: A 72-year-old male presented at age 57 (2007) with new onset IAF. The patient had Allergic Rhinitis since age 20. For IAF he was treated with Metoprolol, Flecanide and Dofenilide but IAF continued. On 3/2/11, TSH was 5.12 ((0.270-4.2 uU/Ml). At age 64 (2014), Catheter Ablation was performed. Before the Ablation, 08/16/2013, the FT4 was 1.2 (0.90-1.70) ng/ml and TSH 3.99 (0.270-4.200) uU/ml. Two years post Ablation, on 1/19/2016, TFTs were: FT4 1.10 (0.90-1.70) ng/ml; TSH 5.42 (0.270-4.200) uU/ml and repeat TFTs on 3/15/16 were: FT4 1.24 (0.90-1.70) ng/dl; TSH 4.10 (0.270-4.2 uU/dl. The diagnosis of Borderline Hypothyroid was entertained. He was trialed on Thyroxine 25 mcg daily with gradual increase to 75 mcg. The patient complained of being light headed, weak and having diffculty concentrating and the TSH was still elevated. Thyroxine was discontinued. In 2017, IAF returned. In October 2019 the thyroid was 35-40 Gm., firm, and with small nodules on palpation and ultrasound. The TFTs on 10/01/2019 were: FT4 0.81 (0.75-1.54) ng/ml and TSH 5.15 (0.3-4.2) uIU/ml. To test whether overproduction of TSH was causing excess Thyroxine release and IAF, low dose Methimazole was started at 5 mg, four days a week. There have been no episodes of AF for the past three years while on Methimazole. TFTs on 10/19/2022 were: FT4 0.94 (0.75-1.54) ng/ml and TSH 7.11 (0.099-4.2) uiU/m). Conclusion: In the clinical setting of IAF, elevated TSH and normal FT4, overproduction of TSH by extrinsic stimuli should be considered. Thyroid partial blockade with Methimazole is safe, economical, and reversible and may give valuable information about whether the thyroid is causing episodic Atrial Fibrillation. Presentation: Thursday, June 15, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10553885/ http://dx.doi.org/10.1210/jendso/bvad114.1177 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Neuroendocrinology & Pituitary
Maher, Thomas D
THU097 Primary Overproduction Of TSH Presenting As Intermittent Atrial Fibrillation Responding To Methimazole
title THU097 Primary Overproduction Of TSH Presenting As Intermittent Atrial Fibrillation Responding To Methimazole
title_full THU097 Primary Overproduction Of TSH Presenting As Intermittent Atrial Fibrillation Responding To Methimazole
title_fullStr THU097 Primary Overproduction Of TSH Presenting As Intermittent Atrial Fibrillation Responding To Methimazole
title_full_unstemmed THU097 Primary Overproduction Of TSH Presenting As Intermittent Atrial Fibrillation Responding To Methimazole
title_short THU097 Primary Overproduction Of TSH Presenting As Intermittent Atrial Fibrillation Responding To Methimazole
title_sort thu097 primary overproduction of tsh presenting as intermittent atrial fibrillation responding to methimazole
topic Neuroendocrinology & Pituitary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553885/
http://dx.doi.org/10.1210/jendso/bvad114.1177
work_keys_str_mv AT maherthomasd thu097primaryoverproductionoftshpresentingasintermittentatrialfibrillationrespondingtomethimazole